Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)
China
· Delayed Price · Currency is CNY 20.66
-0.23 (-1.10%)
Jun 6, 2025, 2:45 PM CST
SHE:300357 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 314.96 | 317.82 | 310.18 | 348.77 | 337.99 | 278.45 | Upgrade
|
| Depreciation & Amortization | 50.68 | 50.68 | 38.46 | 26.08 | 25.07 | 15.03 | Upgrade
|
| Other Amortization | 2.41 | 2.41 | 0.95 | 1.94 | 1.95 | 1.43 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.57 | -0.57 | - | 0.27 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 1.42 | 1.42 | 0.58 | 43.23 | 0.1 | 0.01 | Upgrade
|
| Loss (Gain) From Sale of Investments | -6.47 | -6.47 | -1.24 | -2.69 | -6.29 | -3.99 | Upgrade
|
| Provision & Write-off of Bad Debts | 0.86 | 0.86 | -1 | 1.24 | 1.55 | 0.3 | Upgrade
|
| Other Operating Activities | 32.66 | -12.32 | -13.26 | -11.32 | -11.29 | -8.64 | Upgrade
|
| Change in Accounts Receivable | -99.79 | -99.79 | 66 | -30.95 | -34.58 | -12.17 | Upgrade
|
| Change in Inventory | 1.3 | 1.3 | -9.39 | 4.1 | -5.42 | -11.51 | Upgrade
|
| Change in Accounts Payable | 7.69 | 7.69 | -9.16 | -20.92 | 52.47 | -1.92 | Upgrade
|
| Operating Cash Flow | 304.55 | 262.44 | 382.08 | 360.28 | 360.58 | 256.22 | Upgrade
|
| Operating Cash Flow Growth | -10.93% | -31.31% | 6.05% | -0.08% | 40.73% | 10.00% | Upgrade
|
| Capital Expenditures | -123 | -129.32 | -227.47 | -200.66 | -124.25 | -70.16 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.02 | 0.02 | 0 | 0.22 | - | 0 | Upgrade
|
| Investment in Securities | -443.6 | -478.84 | 5.93 | 24.6 | -109.05 | -27 | Upgrade
|
| Other Investing Activities | 8.69 | 12.54 | 29.66 | 57.64 | 20.99 | 6.42 | Upgrade
|
| Investing Cash Flow | -557.89 | -595.6 | -191.87 | -118.19 | -212.31 | -90.74 | Upgrade
|
| Short-Term Debt Issued | - | 2.76 | 24.99 | - | - | - | Upgrade
|
| Total Debt Issued | 15 | 2.76 | 24.99 | - | - | - | Upgrade
|
| Short-Term Debt Repaid | - | -44.12 | -20 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -7.79 | -8.56 | -5.79 | -5.81 | - | Upgrade
|
| Total Debt Repaid | -74.48 | -51.91 | -28.56 | -5.79 | -5.81 | - | Upgrade
|
| Net Debt Issued (Repaid) | -59.48 | -49.15 | -3.57 | -5.79 | -5.81 | - | Upgrade
|
| Common Dividends Paid | -149.43 | -97.45 | -105.62 | -105.24 | -83.77 | -94.25 | Upgrade
|
| Other Financing Activities | 0.21 | 0.01 | 85.78 | - | - | - | Upgrade
|
| Financing Cash Flow | -208.71 | -146.58 | -23.41 | -111.03 | -89.58 | -94.25 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.01 | 0.01 | 0.01 | 0.02 | -0.01 | -0.03 | Upgrade
|
| Net Cash Flow | -462.05 | -479.73 | 166.8 | 131.08 | 58.67 | 71.21 | Upgrade
|
| Free Cash Flow | 181.55 | 133.12 | 154.61 | 159.62 | 236.33 | 186.06 | Upgrade
|
| Free Cash Flow Growth | 25.44% | -13.89% | -3.14% | -32.46% | 27.02% | 44.27% | Upgrade
|
| Free Cash Flow Margin | 19.36% | 14.39% | 18.23% | 17.82% | 29.26% | 29.25% | Upgrade
|
| Free Cash Flow Per Share | 0.35 | 0.25 | 0.29 | 0.30 | 0.45 | 0.35 | Upgrade
|
| Cash Income Tax Paid | 104.85 | 98.34 | 80.89 | 114.73 | 39.38 | 70.62 | Upgrade
|
| Levered Free Cash Flow | 83.8 | 95.1 | 100.31 | 41.7 | 125.17 | 94.12 | Upgrade
|
| Unlevered Free Cash Flow | 84.4 | 95.77 | 101.13 | 41.98 | 125.4 | 94.12 | Upgrade
|
| Change in Net Working Capital | 41.54 | 26.36 | -97.34 | 24.17 | -6.36 | 26.97 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.